UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024

Humacyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)

001-39532 (Commission File Number)

85-1763759 (I.R.S. Employer Identification Number)

27713

(Zip code)

2525 East North Carolina Highway 54 Durham, NC

(Address of principal executive offices)

(919) 313-9633 (Registrant's telephone number, including area code)

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	HUMA	The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of	HUMAW	The Nasdaq Stock Market LLC
Common Stock at an exercise price of \$11.50		

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 🗵

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01. Other Events.

On February 29, 2024, Humacyte, Inc. (the "Company") made available an investor presentation (the "Investor Presentation"), which the Company expects to use in connection with investor calls and/or conferences. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	
Number	Description
99.1	Humacyte, Inc. Investor Presentation February 2024
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMACYTE, INC.

By:

Date: February 29, 2024

/s/ Dale A. Sander

 Name:
 Dale A. Sander

 Title:
 Chief Financial Officer, Chief Corporate Development Officer and Treasurer



Disclaimer



These slides and the accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included in these slides and the accompanying oral presentation are forward-looking statements reflecting management's current beliefs and expectations. In some cases, you can identify forward-looking statements by terminology. Forward-looking statements in these slides and the accompanying oral presentation include, but are not limited to, statements about our plans and isplite to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our plans, anticipated timelines and ability to obtain marketing approval from the U.S. Food and Drug Administration ("FDA") and other regulatory authorities, including the European Medicines Agency, for our bioengineered human accellular vessels ("HAVs") and other product candidates, including our Biologics License Application seeking approval of the HAV in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated and when autologous vein use is not feasible; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates, including the design of our clinical trials; our anticipated growth rate and market opportunities; the potential liquidity and trading of our securities; our ability to canise additional capital in the future; our ability to commercial needs; our exportatives is presented to additional product candidates; the entrace to the straget populations for our product candidates; and anticipated benefits of our HAVs and reimbursement; our ability to obtain and maintain intellectual property rights of others; our ability to mainfacture HAVs and other product candidates in dividing our bioliding to third-party manyfacturers, our inclinated in the resence of other third parties on which we rely, including our tradicates as well as our ability to thrad-party cov

Humacyte is a Leader the Field of Regenerative Medicine: Investigational Bioengineered Tissues & Organs





Category-Defining Innovation that Creates New Tissues

Universally Implantable Regenerative Human Tissue






Humacyte Leadership & Board



Leadership Team	Board of Directors	Prior Experience
	Kathleen Sebelius Chair of the Board	AstraZeneca
Laura E. Niklason, MD, Dale Sander PhD Chief Financial Officer, Heather Prichard, PhD Founder, President, Chief Corporate Chief Operating Officer Chief Executive Officer Development Officer	Gordon M. Binder Emery N. Brown, MD, PhD	bluebirdbio (th Bristol Myers Squibb
	Michael T. Constantino Brady W. Dougan Charles Bruce Green, MD	U.S.Department of Heath and Human Services
Shamik Parikh, MD Cindy Cao BJ Scheessele Chief Medical Officer Chief Regulatory Officer Officer	Laura E. Niklason, MD, PhD	Johnson Johnson KRIYA
	Todd M. Pope Diane Seimetz, PhD Rajiv Shukla	NOVARTIS
Sabrina Osborne William Tente, MS Harold Alterson Executive Vice Executive Senior Vice President, Regulatory Fellow President, Quality Business Strategy & People	Max Wallace, JD Susan Windham-Bannister, PhD	Yale University School of Medicine

Platform & Manufacturing: Enable Broad Pipeline of Regenerative Medicine Products






Pipeline with Multiple Potential Commercial Launches




	Preclinical	Phase 1/2	Phase 3
Vascular Tissue Constructs (HAV)			
Trauma			
Dialysis (AV Access)			
PAD			
Pediatric Heart Disease			
CABG			
Complex Tissue Constructs			
Urinary Conduit			
Tracheal Replacement			
Esophageal Replacement			
Complex Organ Systems			
BioVascular Pancreas (T1D)			
Lung			

HAV Observed to Repopulate with Patient's Own Cells Potentially Enabling Infection Resistance & Self-Healing







Vascular Injuries – Value Proposition for the HAV



- Common causes of vascular injuries include workplace injuries, car accidents, gunshots and stabbings, and sports injuries
- Currently available treatment options have significant drawbacks:







Why HAV for Traumatic Vascular Injury?

• HAV is off the shelf and immediately available for implant

- In contrast to harvesting vein from the patient which can take an hour ¹
- HAV repopulates with the patient's cells, becoming a living tissue ²



• HAV is resistant to infection, compared to synthetic grafts ³



Zenati, M.S., et al, New England Journal of Medicine 2019; 380: 2.
 Kirkton, R.D., et al, Science Translational Medicine 2019; 11:eaau6934.
 Wang, J., et al, Journal of Vascular Surgery – Vascular Science 2023; 4: 100120.

CLN-PRO-V005 Phase 2/3 Pivotal Trial

Human Acellular Vessel (HAV) in Vascular Trauma (NCT03005418)

Single-arm, open label trial
Level 1 trauma centers in US

and Israel

· Arterial injury repair

 Primary endpoint 30-day patency in patients with extremity injuries

69 total patients enrolled as of data cut off 51 patients with extremity injuries – focus for BLA filing

- · ALL patients had NO VEIN for repair, as assessed by treating surgeons
- Hence, patients would have received synthetic grafts, ligation of the bleeding vessel and/or amputation, had they not gotten the HAV.
- Extremity Injuries at high risk of contamination/infection¹
- 12 1: Prevaldi et al, 2016 World Journal of Emergency Surgery

- Historical Benchmarks
 Systematic literature review of synthetics in vascular trauma
- Primary Comparison
 30-day endpoint of patency
- Secondary Comparisons
 Infection rate
 - > Amputation rate

Success Oriteria

- Comparable (or higher) Patency
- Infection rate comparable or lower than Synthetic Grafts
- Amputation rate comparable or lower than Synthetic Grafts
- > No unexpected safety signals

Humacyte

Example Vascular Injuries Treated in CLN-PRO-V005 Trial





Gunshot Wound



Industrial Accident



Knee Dislocation

V005 Trial: HAV vs Synthetic Graft Benchmarks

Endpoint	HAV Extremity (V005) %	Synthetic Graft Benchmark %
Secondary Patency	90.2%	78.9%
Conduit Infections	2.0%	8.4%
Amputations	9.8%	24.3%

V005 Trial was a Success and Met All Objectives

Observations from V005 trial:

Secondary Patency
 HAV performed better

than historic benchmark

Conduit Infections

 HAV point estimate lower than historic benchmark

Amputations

 HAV performed better than historic benchmark


Humacyte[®]

Ukraine Real World Experience of HAV Use in Vascular Repair



- 19 patients received a HAV
- 17 consented for data collection and study participation
- 16 patients had extremity trauma repair; one patient required HAV for latrogenic Trauma Repair
- Ukraine Humanitarian Experience presented at MHSRS¹ 2023 Annual meeting on August 14th 2023

Measure	V017 Trial Ukraine Extremity Patients (n=16)
30-day Patency	93.8%
Amputation	0.0%
Limb Salvage	100.0%
Conduit Infection	0.0%



1: MHSRS - Military Health System Research Symposium

15

HAV Combined Results from V005 and V017 Trial	HAV	Combined	Results	from	V005	and	V017	Trials
---	-----	----------	---------	------	------	-----	------	--------

The FDA advised Humacyte to include in its BLA submission patient
outcomes from V017 (the humanitarian program conducted in Ukraine)

Endpoint	HAV Extremity (V005 + V017 Meta Analysis) %	Synthetic Graft Benchmark %			
Secondary Patency 91.5% 78.9%					
Conduit Infections 0.9% 8.4%					
Amputations 4.5% 24.3%					
Combined V005 + V017 Results Further Supports HAV Performance Versus					

Synthetic Graft Benchmarks

16

- Observations from combined V005 and V017 trials:
- Secondary Patency
 - HAV performed better than historic benchmark

Conduit Infections

 HAV performed better than historic benchmark

Amputations

 HAV performed better than historic benchmark

👬 Humacyte

Priority Review of BLA and Planned Market Launch




- BLA submitted to FDA in December 2023
- Priority Review granted by FDA in February 2024
- PDUFA date of August 10, 2024
- Factors supporting Priority Review:
 - In May 2023 the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for use of the HAV in urgent arterial repair following extremity vascular trauma
 - The HAV was assigned a priority designation by the Secretary of Defense under Public Law 115-92, enacted to expedite the FDA's review of products that are intended to diagnose, treat or prevent serious or life-threatening conditions facing American military personnel
- Planned market launch in 2nd Half 2024 if approved

17



AV Access for Hemodialysis Has Substantial Limitations





HAV is Designed to Address Failures in AV Access




HAV Expected Economic Benefits Expected Improved Patient Outcome · Expected reduction in catheter contact time, · HAV usable for dialysis after only four weeks infection, and failure rate have potential to • HAV reduces catheter contact time, thereby reduce costs, including the following: reducing risk of catheter infection >90% of HAVs functional for dialysis at 6 months Reduce Costs from HAV infection rate is <1% per patient year **RMAT** designation Reduce Costs of Additional granted by FDA Access Procedures

Lawson, J.H, et al, The Lancet 2016; 387: 2026-2034. Halbert, R.J., et al, Kidney360 2020; doi: 10.34067/KID.003502020

Enrolled Phase 3 Trial in Dialysis: HAV vs. Fistula

21

V007 Phase 3 Trial Design: Compare the Efficacy and Safety of Humacyte's Human Acellular Vessel with that of an Autologous Arteriovenous Fistula in Subjects with End-Stage Renal Disease



> Endpoints

- Efficacy: Useability for dialysis and patency during the first year
- Safety: interventions, infections, etc.

> Duration

Subjects followed for 24 months after implantation


> Stes


30 centers in the U.S.

> Timelines


Top-line readout expected in 2024 (12-month follow-up from last subject enrolled)


🕂 Humacyte

















Potentially Transforming CABG Care: Greater Durability, Less Morbidity



Saphenous Vein Graft (SVG) Harvesting SVG from the patient is painful and complicated:

- 41% have persistent numbness
- 32% develop infection

28

- 23% have persistent swelling; worse in obese and diabetic patients; 2x worse in women
- SVGs do not last long enough: ~33% of patients will require one or more regrafting procedures during their lifetimes

Humacyte's HAV


- Does not require tissue harvest from the patient
- Immediately available and avoids morbidity of vein harvest
- Particularly important to avoid vein harvest in diabetics, women, and the overweight
- Durable and highly uniform in diameter and quality






Surgeons know what they are getting each time






- Testing of HAV in baboon model has transitioned to right coronary
- Results showing HAV maintained patency and exhibited host-cell



Humacyte HAV in Baboon






Biovascular Pancreas May Deliver Curative Islets to Diabetics





- · Islets die after injection into the liver, due to lack of oxygen and nutrients
- Humacyte's HAV is being developed as a means to provide oxygen and nutrients to islets that are coated on the outside: "Biovascular Pancreas" (BVP)
- Once implanted in the vasculature, blood flow supplies oxygen and nutrients to islets
- One 42-cm HAV is expected to accommodate all the islets in an entire human pancreas



Primate BVP – Islets Survive, and Produce Insulin




- In this model, the BVP is produced by harvesting islets from one animal, and creating a BVP comprising human HAV and primate islets
- · Animal receives the primate-islet BVP into the aorta
 - 25,600 islet equivalents

34

 Corresponds to a potentially curative number of islets in a human




Islets survive for weeks after implantation, continue making insulin (c-peptide).





Our Technology Addresses Compelling Unmet Needs in Attractive Markets





36

Preparing for Strong Commercial Launch



	 Majority of trauma vascular repair performed at Level 1 centers Approximately 200 level 1 trauma centers in U.S. Clear call point as majority of cases performed by vascular surgeons Humacyte expects DoD to stockpile for deployment to sites of conflicts
	 Budget Impact Model expected to support economic benefit of HAV Costs associated with complications in vascular trauma potentially avoided with HAV: Amputation Infection Harvest Site Infection Opportunity for incremental CMS and private pay NTAP payment
1/	 Estimate we can reach market with fewer than 20 sales representatives Direct force expected to secure hospital approvals through VACs and also drive adoption by vascular surgeons
Strategic Collaboration	 Large shareholder with \$175 million invested in Humacyte Global collaboration for HAV in trauma, dialysis and PAD Largest provider of renal care services in the U.S.
	l / Strategic

Commercial Manufacturing Scale – LUNA200 System

Bioreactor bag

Each bioreactor bag contains a single polymer mesh scaffold, seeded with banked human cells



Growth drawer 10 bioreactor bags per growth drawer; tubing connects to shared nutritive media



Each LUNA200 System Each LUNA200 can produce 200 HAVs per batch (or ~1,000 HAVs annually) ¹




Commercial 83,000 sq ft Bioprocessing Facility

- Currently operating 8 LUNA200 systems
- Annual Capacity expected to exceed 40,000 HAVs
- Functionally closed system with state-of-the-art process automation




Anticipated 2024 Milestones





The Promise of Regenerative Medicine



40

Humacyte



Universally Implantable Regenerative Human Tissue

Thank You